THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
Repatha (evolocumab) isn’t known to interact with other medications, supplements, herbs, vitamins, vaccines, or lab tests. There are no known direct interactions between Repatha and alcohol. However, ...
In the persistence and adherence analysis, which looked at 28 studies including 267,542 patients, Amgen found that 69% of ...
--Amgen today announced new Repatha ® combined data from the Phase 3 FOURIER and FOURIER Open Label Extension studies and the Phase 2 OCEAN- DOSE study of investigational olpasiran, an siRNA that ...
--Amgen today announced the presentation of 12 cardiovascular scientific research abstracts, including clinical trial and real-world evidence studies of Repatha ®, that add to the growing body of ...
Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...
THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from the Phase 3 VESALIUS-CV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results